Aldeyra Therapeutics financials
$1.32+13.79%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$35.3M | -$60.1M | -$42.8M | -$62.7M | -$56.2M | -$36.4M | -$63.1M | -$39.7M | -$22.5M | -$18.7M |
| Net income | -$33.8M | -$55.9M | -$37.5M | -$62.0M | -$57.8M | -$37.6M | -$60.8M | -$38.9M | -$22.3M | -$18.7M |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.56 | $-0.94 | $-0.64 | $-1.06 | $-1.07 | $-1.11 | $-2.24 | $-1.79 | $-1.40 | $-1.65 |
| EBITDA | -$35.0M | -$59.9M | -$42.5M | -$62.4M | -$56.0M | -$36.4M | -$63.0M | -$39.6M | -$22.5M | -$18.7M |
| Operating cash flow | -$33.3M | -$43.2M | -$30.3M | -$56.6M | -$42.6M | -$37.5M | -$45.0M | -$29.9M | -$19.2M | -$15.1M |
| Free cash flow | -$33.3M | -$43.2M | -$30.3M | -$56.7M | -$42.6M | -$37.5M | -$45.0M | -$30.1M | -$19.2M | -$15.2M |
| Diluted shares | 60.1M | 59.5M | 58.9M | 58.4M | 54.0M | 34.0M | 27.1M | 21.7M | 15.9M | 11.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $70.0M | $54.5M | $142.8M | $144.4M | $104.8M | $52.9M |
| Short-term investments | $0.00 | $46.6M | $0.00 | $29.9M | $0.00 | $0.00 |
| Total debt | $15.2M | $15.0M | $15.1M | $15.8M | $15.5M | $15.1M |
| Total assets | $72.1M | $104.6M | $148.3M | $181.3M | $233.1M | $83.4M |
| Total liabilities | $27.8M | $33.6M | $28.5M | $30.3M | $27.4M | $23.8M |
| Shareholders' equity | $44.3M | $71.0M | $119.8M | $151.0M | $205.7M | $59.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology